Ivy P. Altomare, MD

home / authors / ivy-p-altomare-md

Articles

Dr. Altomare on Investigational Agents in ITP

Dr. Altomare on Investigational Agents in ITP

Ivy P. Altomare, MD
May 23rd 2020

Ivy P. Altomare, MD, discusses investigational agents in immune thrombocytopenia.

Read More

Dr. Altomare on the Challenges of Treating ITP

Dr. Altomare on the Challenges of Treating ITP

Ivy P. Altomare, MD
April 24th 2020

Ivy P. Altomare, MD, discusses some of the challenges of treating patients with immune thrombocytopenia.

Read More

Dr. Altomare on Treatment Options in ITP

Dr. Altomare on Treatment Options in ITP

Ivy P. Altomare, MD
April 1st 2020

Ivy P. Altomare, MD, discusses treatment options for patients with immune thrombocytopenia purpura.

Read More

Dr. Altomare on the Management of ITP

Dr. Altomare on the Management of ITP

Ivy P. Altomare, MD
March 26th 2020

Ivy P. Altomare, MD, discusses the management of patients with immune thrombocytopenia purpura.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data